Immunophotonics, Inc. announced two important milestones supporting the company’s continued advancement of Interventional Immuno-Oncology®: the closing of more than $10 million in Series C financing and the appointment of Robert H. Arch, Ph.D., as President and Chief Executive Officer.

The financing reflects the continued confidence of the company’s investors in its science, strategy, and team. The proceeds will provide additional resources to advance IP-001 through clinical development and pursue opportunities that support the company’s long-term objectives.

Immunophotonics also recognizes Miguel Zubizarreta for his leadership and commitment during a pivotal period in the company’s evolution. Zubizarreta will continue to support the company as a long-term investor and member of its Board of Directors.

These milestones reflect the collective efforts of Immunophotonics’ employees, investors, clinical collaborators, and partners, who share the company’s vision for advancing innovative approaches to cancer treatment.

Read the full press release